Echo Therapeutics to Present Clinical Study Results of Its Symphony Transdermal Continuous Glucose Monitoring System at Annual Diabetes Technology Meeting
FRANKLIN, Mass., Nov. 13 /PRNewswire-FirstCall/ -- Echo Therapeutics (OTC
Bulletin Board: ECTE) announced today that it will present clinical trial data
this evening at the Eighth Annual Diabetes Technology Meeting in Bethesda,
Maryland. The abstract entitled, "Transdermal Glucose Monitoring Enabled by
Prelude(TM) SkinPrep System" will be presented at a poster session from 6:00-
8:00 and will highlight the positive results from the most recent clinical
trial of Echo's Symphony(TM) tCGM System, a non-invasive (needle-free)
transdermal continuous glucose monitoring (tCGM) system, in patients with Type
1 and Type 2 diabetes. The Annual Diabetes Technology Meeting is one of the
largest gatherings of technology developers and heath care professionals
focused on delivering leading-edge, cost-effective technologies to help people
with diabetes.
The Symphony(TM) tCGM System measures the continuous flow of glucose
through the skin, which is made permeable with Echo's Prelude(TM) SkinPrep
System, a leading-edge skin permeation device. Information about the meeting
can be found on the Diabetes Technology Society website at:
http://www.diabetestechnology.org/index.html
"We are excited to present these positive clinical trial results in a
peer-reviewed setting as we continue to build awareness of our Symphony tCGM
System. These clinical results represent substantial progress in our Symphony
development program," stated Patrick T. Mooney, M.D., Echo's Chairman and CEO.
"The frequent reference blood measurements in this study with a YSI laboratory
analyzer enabled us to evaluate Symphony's performance with a high level of
confidence. We believe Symphony's safety and accuracy data from this study are
comparable to all FDA-approved invasive (needle-based) CGM devices. We look
forward to continued progress in our late-stage Symphony development
programs."
About Echo Therapeutics
Echo Therapeutics is focused on transdermal medical devices and specialty
pharmaceuticals. Echo is developing the Symphony tCGM System as a
non-invasive, wireless, transdermal continuous glucose monitoring (tCGM)
system for people with diabetes and for use in hospital critical care units,
together with a wide range of novel transdermal reformulations of FDA-approved
products.
Forward Looking Statements
Echo's Symphony tCGM System has not yet been approved for sale. The
regulatory approval process for the Symphony tCGM System involves, among other
things, successfully completing clinical trials and obtaining a premarket
approval, or PMA, from the FDA and corresponding foreign regulatory
authorities. The PMA process requires Echo to prove the safety and efficacy of
the Symphony tCGM System to the FDA's satisfaction. This process can be
expensive and uncertain, and there is no guarantee that Echo will be able to
submit a PMA for the Symphony tCGM System or that such system will be approved
by the FDA in any specific timeframe, or at all. In addition, clinical testing
of Echo's products and eventual commercialization of its products are subject
to all of the risks and uncertainties set forth in its periodic reports filed
with the U.S. Securities and Exchange Commission.
(C) 2002 - 2008 Echo Therapeutics, Inc. All rights reserved worldwide.
Investor Relations Contacts:
Patrick T. Mooney, M.D.
Chairman & CEO
Echo Therapeutics
508-530-0329
